On August 28, Moderna, Inc. fell 4.41% in regular trading, trading at approximately $137.29/share, with turnover of $459 million.

The decline was driven by the company announcing it upsized its private placement of zero-coupon convertible senior notes due 2032 from the previously announced $2 billion to $2.6 billion, while granting initial purchasers an option to acquire up to an additional $400 million of notes. The initial conversion price was set at approximately 47.5% premium to the August 27 closing price of $142.77, with capped call transactions establishing an initial cap price of $392.62, representing a 175% premium. The stock had already fallen 5.57% in the prior session when the initial $2 billion plan was first disclosed. Proceeds are expected to fund capped call transaction costs, potential investments in the oncology business, and debt repayment. Despite a same-day Argus Research upgrade to Buy with a $180 price target and FDA approval expanding its updated Spikevax vaccine to broader populations, dilution concerns from the enlarged offering dominated market sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)